Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. 

Type
Public
HQ
South San Francisco, US
Size (employees)
13 (est)
Innoviva is headquartered in South San Francisco, US

Innoviva Office Locations

Innoviva has office in South San Francisco
South San Francisco, US

Innoviva Metrics

Innoviva Summary

Market capitalization

$1.24 B

Closing share price

$11.5
Innoviva's current market capitalization is $1.24 B.

Innoviva Financials

Innoviva's revenue is $53.9 M in FY, 2015 which is a 539.74% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$53.9 M$8.43 M$4.76 M

Net Income

$-18.8 M$-168 M$-171 M

Innoviva Market Value History

Innoviva News

Innoviva Company Life